Company Reports

Sartorius AG is a leading provider of bioprocessing equipment and consumables, offering a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions, and its focus as a pure-play biopharmaceutical equipment supplier distinguish Sartorius AG from more diversified competitors. Sartorius AG further reinforces its competitive edge by leading the market in bioreactors, a core component of the biomanufacturing process.

Sartorius AG is a leading provider of bioprocessing equipment and consumables, offering a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions, and its focus as a pure-play biopharmaceutical equipment supplier distinguish Sartorius AG from more diversified competitors. Sartorius AG further reinforces its competitive edge by leading the market in bioreactors, a core component of the biomanufacturing process.

Sartorius Group reported second-quarter results with 7.9% organic sales growth, excluding US tariff surcharge compensation and currency effects, and underlying EBITDA margin expanding to 30.8% from 29.9% year over year. Management confirmed their full-year guidance.

Sartorius Group reported first-quarter constant-currency sales growth of 7.5%, with both segments contributing to the increase. Underlying EBITDA margin declined 10 basis points to 29.7%. Management maintained its full-year guidance.

Sartorius AG is a leading provider of bioprocessing equipment and consumables, offering a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions, and its focus as a pure-play biopharmaceutical equipment supplier distinguish Sartorius AG from more diversified competitors. Sartorius AG further reinforces its competitive edge by leading the market in bioreactors, a core component of the biomanufacturing process.

Life science stocks have been under pressure since late 2022, but with profits expected to rebound in the high single digits in 2026 on average and potentially accelerate even further in 2027-30 due to upcoming catalysts, we see growing momentum in the industry’s profit growth trajectory.

Sartorius Group reported its preliminary full-year 2025 results with 7.6% growth in constant currencies and an adjusted EBITDA margin of 29.7%, both in line with the company-compiled consensus.

Sartorius AG is a leading provider of bioprocessing equipment and consumables, offering a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions, and its focus as a pure-play biopharmaceutical equipment supplier distinguish Sartorius AG from more diversified competitors. Sartorius AG further reinforces its competitive edge through market leadership in bioreactors, which are core components of the biomanufacturing process.

Sartorius Group reported positive third-quarter results as revenue and adjusted EBITDA were above company-compiled consensus. Sales increased 10.6% in constant currency, and adjusted EBITDA increased by 14.8%. Shares are trading 10% higher intraday.

Sartorius Group reported its second-quarter 2025 results, where the slight revenue miss was offset by an underlying EBITDA beat against company-reported consensus. Sales increased 5.7% in constant currency, while underlying EBITDA increased by 11.5%. Shares are trading 10% lower intraday on July 22.

We are transferring coverage of Sartorius AG and its subsidiary Sartorius Stedim Biotech—both active in biopharmaceutical equipment and laboratory consumables—to a new analyst. Sartorius Stedim Biotech accounts for approximately 80% of group revenue and 89% of EBIT.

Sartorius AG is a leading provider of bioprocessing equipment and consumables, offering a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions, and its focus as a pure-play biopharmaceutical equipment supplier distinguish Sartorius AG from more diversified competitors. Sartorius AG further reinforces its competitive edge through market leadership in bioreactors, which are core components of the biomanufacturing process.

Over the past week, life science shares have experienced significant volatility related to a deepening trade war with China and as broader US tariffs were implemented and then paused for 90 days to allow time for negotiations. A pharmaceutical-specific tariff is also being considered.

Life science toolmakers that enable drug production operate attractive businesses for two major reasons that investors often find compelling. First, regulation of the drug manufacturing process creates highly durable switching costs for end users and long potential revenue streams for life science toolmakers. Second, life science firms often benefit from broad exposure to biopharmaceutical growth without taking on much product-specific risk.

Most medical technology and device companies under our coverage have economic moats, but attractive valuations are hard to find, and the sector trades at an average price/fair value estimate of 1.33.